Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb: Mead Johnson Enfamil infant formula sales fell 12% to $186 mil. in the first quarter, although nutritional division's performance for Q1 is "on plan," BMS asserts in April 25 earnings announcement. Total nutritional sales fell 8% to $463 mil. during the quarter, with international revenue up 8% and U.S. sales declining 18%. BMS division began rolling out DHA/ARA-fortified Enfamil LIPIL during the quarter. Worldwide consumer medicine sales dropped 16% to $96 mil. Total consolidated revenue, excluding nonrecurring items, fell 7% to $4.34 bil., with net earnings from continuing operations, excluding nonrecurring items, falling 30% to $875 mil...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel